Entheon Biomedical

BioTech Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
NASDAQ REGN REGENERON PHARMACEUTICALS
US$ 595.40
4.27 0.72
368,286
108.03M
US$ 64.320B
NASDAQ MRNA MODERNA
US$ 149.95
7.10 4.97
4.77M
397.76M
US$ 59.640B
NASDAQ BNTX BIONTECH
US$ 157.50
8.40 5.63
1.32M
243.02M
US$ 38.280B
NASDAQ CERT CERTARA
US$ 22.09
0.63 2.94
409,861
159.84M
US$ 3.530B
NASDAQ ROIV ROIVANT SCIENCES
US$ 4.42
0.35 8.60
955,481
692.07M
US$ 3.060B
NASDAQ ABCL ABCELLERA BIOLOGICS
US$ 10.64
-0.01 -0.09
1.97M
281.58M
US$ 3.000B
NYSE DNA GINKGO BIOWORKS
US$ 2.38
0.00000 0.00000
15.66M
1.09B
US$ 2.590B
NASDAQ EQRX EQRX
US$ 4.55
-0.14 -2.99
1.27M
487.76M
US$ 2.220B
NASDAQ KRYS KRYSTAL BIOTECH
US$ 67.47
1.81 2.76
177,482
25.64M
US$ 1.730B
NASDAQ BBIO BRIDGEBIO PHARMA
US$ 9.92
0.84 9.25
2.49M
147.69M
US$ 1.470B
NASDAQ RXRX RECURSION PHARMACEUTICALS
US$ 8.43
0.29 3.56
934,314
159.52M
US$ 1.340B
NASDAQ SANA SANA BIOTECHNOLOGY
US$ 6.51
0.08 1.24
1.41M
189.67M
US$ 1.230B
NASDAQ KYMR KYMERA THERAPEUTICS
US$ 21.10
1.41 7.16
571,623
51.72M
US$ 1.090B
NASDAQ SAVA CASSAVA SCIENCES
US$ 26.51
-1.61 -5.73
736,444
40.08M
US$ 1.060B
NASDAQ MRUS MERUS
US$ 22.33
-0.31 -1.37
166,044
43.55M
US$ 972.470M
NASDAQ BLTE BELITE BIO
US$ 37.69
6.55 21.03
100,909
24.10M
US$ 908.330M
NASDAQ AVXL ANAVEX LIFE SCIENCES
US$ 10.30
0.29 2.90
632,353
77.41M
US$ 797.320M
NASDAQ DSGN DESIGN THERAPEUTICS
US$ 14.09
0.09 0.64
94,391
55.66M
US$ 784.250M
NYSE NUVB NUVATION BIO
US$ 3.52
0.28 8.64
1.00M
217.13M
US$ 764.300M
NASDAQ NKTX NKARTA
US$ 13.18
0.86 6.98
514,246
48.40M
US$ 637.910M
NASDAQ AMRS AMYRIS
US$ 1.93
0.08 4.32
3.56M
319.71M
US$ 617.040M
NASDAQ NUVL NUVALENT
US$ 13.55
-0.01 -0.07
85,204
42.88M
US$ 581.020M
OTCMKTS NWBO NORTHWEST BIOTHERAPEUTICS
US$ 0.63
0.00200 0.32
789,281
851.56M
US$ 538.190M
NASDAQ BCYC BICYCLE THERAPEUTICS
US$ 17.49
0.71 4.23
141,400
29.65M
US$ 518.580M
NASDAQ CNTA CENTESSA PHARMACEUTICALS
US$ 5.17
0.30 6.16
90,913
94.04M
US$ 486.190M
NASDAQ CMPS COMPASS PATHWAYS
US$ 10.80
-0.02 -0.18
164,906
42.51M
US$ 459.110M
NASDAQ ESPR ESPERION THERAPEUTICS
US$ 6.45
0.09 1.42
605,951
63.01M
US$ 406.410M
NASDAQ EWTX EDGEWISE THERAPEUTICS
US$ 8.08
0.12 1.51
103,805
49.58M
US$ 400.610M
NASDAQ BNGO BIONANO GENOMICS
US$ 1.34
-0.04 -2.90
5.83M
289.70M
US$ 388.200M
NASDAQ VERA VERA THERAPEUTICS
US$ 13.27
-0.34 -2.50
58,638
26.77M
US$ 355.240M
NASDAQ HLVX HILLEVAX
US$ 10.50
-0.43 -3.93
74,665
33.43M
US$ 351.020M
NASDAQ HUMA HUMACYTE
US$ 3.29
0.08 2.49
196,402
103.00M
US$ 338.870M
NASDAQ BMEA BIOMEA FUSION
US$ 11.15
-0.83 -6.93
134,344
29.17M
US$ 325.250M
NASDAQ ABSI ABSCI
US$ 3.33
0.01 0.30
161,405
92.85M
US$ 309.190M
NASDAQ LXRX LEXICON PHARMACEUTICALS
US$ 1.94
0.08 4.30
1.14M
149.59M
US$ 290.200M
NASDAQ GRNA GREENLIGHT BIOSCIENCES
US$ 2.31
0.10 4.52
95,744
123.20M
US$ 284.590M
NASDAQ OMIC SINGULAR GENOMICS SYSTEMS
US$ 4.02
0.20 5.24
315,924
70.59M
US$ 283.770M
NASDAQ AADI AADI BIOSCIENCE
US$ 12.77
0.45 3.65
58,452
20.94M
US$ 267.400M
NASDAQ RANI RANI THERAPEUTICS
US$ 10.63
0.30 2.90
36,652
24.49M
US$ 260.330M
NASDAQ ICVX ICOSAVAX
US$ 6.44
0.71 12.39
553,482
39.73M
US$ 255.860M
NASDAQ RLYB RALLYBIO
US$ 7.54
-0.01 -0.13
33,996
32.13M
US$ 242.260M
NASDAQ PEPG PEPGEN
US$ 10.21
0.28 2.82
33,383
23.63M
US$ 241.260M
NASDAQ EVLO EVELO BIOSCIENCES
US$ 2.15
0.04 1.90
124,756
107.91M
US$ 232.010M
NASDAQ TNYA TENAYA THERAPEUTICS
US$ 5.45
-0.18 -3.20
56,475
41.31M
US$ 225.140M
NASDAQ VECT VECTIVBIO
US$ 5.75
0.35 6.48
41,109
39.03M
US$ 224.420M
NASDAQ IMPL IMPEL PHARMACEUTICALS
US$ 9.22
-0.10 -1.07
49,509
23.18M
US$ 213.720M
NYSEAMEX ZOM ZOMEDICA
US$ 0.21
-0.01 -5.59
22.92M
979.90M
US$ 203.620M
NASDAQ IXHL INCANNEX HEALTHCARE
US$ 3.72
-0.14 -3.63
7,858
51.29M
US$ 190.540M
NASDAQ VOR VOR BIOPHARMA
US$ 4.81
-0.16 -3.22
65,656
37.60M
US$ 180.860M
NASDAQ OMGA OMEGA THERAPEUTICS
US$ 3.63
-0.17 -4.47
143,240
47.85M
US$ 173.700M
NASDAQ GRPH GRAPHITE BIO
US$ 2.82
0.07 2.55
487,374
57.97M
US$ 163.480M
NASDAQ NVCT NUVECTIS PHARMA
US$ 11.99
0.79 7.05
13,584
12.72M
US$ 152.510M
NASDAQ IKNA IKENA ONCOLOGY
US$ 4.20
-0.23 -5.19
63,126
36.16M
US$ 151.870M
NASDAQ FNCH FINCH THERAPEUTICS
US$ 2.83
-0.01 -0.35
41,713
47.56M
US$ 134.590M
NASDAQ IMRX IMMUNEERING
US$ 5.00
-0.41 -7.58
38,661
26.39M
US$ 131.950M
NASDAQ BIOR BIORA THERAPEUTICS
US$ 0.70
-0.00120 -0.17
736,410
184.20M
US$ 128.720M
NASDAQ ANEB ANEBULO PHARMACEUTICALS
US$ 5.49
0.29 5.58
84,786
23.34M
US$ 128.130M
NASDAQ CFRX CONTRAFECT
US$ 3.10
0.03 0.98
79,724
39.33M
US$ 121.920M
NASDAQ CDXC CHROMADEX
US$ 1.67
0.00000 0.00000
722,042
68.33M
US$ 114.110M
OTCMKTS RVVTF REVIVE THERAPEUTICS
US$ 0.36
0.00910 2.60
380,670
317.06M
US$ 113.860M
NASDAQ DBTX DECIBEL THERAPEUTICS
US$ 4.12
-0.09 -2.14
661,805
24.96M
US$ 102.840M
NASDAQ RAIN RAIN THERAPEUTICS
US$ 5.38
-0.18 -3.24
613,940
18.80M
US$ 101.140M
NYSE ANVS ANNOVIS BIO
US$ 12.07
0.73 6.44
49,777
8.16M
US$ 98.490M
NASDAQ PRTG PORTAGE BIOTECH
US$ 7.09
0.11 1.58
28,681
13.35M
US$ 94.650M
NASDAQ TALS TALARIS THERAPEUTICS
US$ 2.30
-2.21 -49.00
3.20M
40.31M
US$ 92.710M
NASDAQ IPA IMMUNOPRECISE ANTIBODIES
US$ 3.84
0.04 1.05
1,767
23.54M
US$ 90.390M
NASDAQ ADAG ADAGENE
US$ 1.99
-0.08 -3.67
80,643
43.79M
US$ 87.140M
NASDAQ DYAI DYADIC INTERNATIONAL
US$ 3.04
-0.01 -0.33
17,553
28.26M
US$ 85.910M
NASDAQ SNTI SENTI BIOSCIENCES
US$ 1.91
-0.06 -2.80
241,025
43.66M
US$ 83.390M
NASDAQ CRDL CARDIOL THERAPEUTICS
US$ 1.34
0.02 1.52
31,735
61.93M
US$ 82.990M
NASDAQ LVTX LAVA THERAPEUTICS
US$ 3.16
0.21 6.95
730
25.78M
US$ 81.340M
NASDAQ HOOK HOOKIPA PHARMA
US$ 1.54
-0.09 -5.52
310,711
50.87M
US$ 78.340M
NASDAQ GALT GALECTIN THERAPEUTICS
US$ 1.31
0.00000 0.00000
65,895
59.39M
US$ 77.800M
OTCMKTS KNWN KNOW LABS
US$ 2.50
0.14 5.82
13,085
30.40M
US$ 76.000M
NASDAQ GMTX GEMINI THERAPEUTICS
US$ 1.72
0.03 1.78
131,707
43.23M
US$ 74.360M
NASDAQ LHDX LUCIRA HEALTH
US$ 1.86
0.00000 0.00000
38,480
39.87M
US$ 74.160M
NASDAQ BOLT BOLT BIOTHERAPEUTICS
US$ 1.93
-13.36 -87.38
150,836
37.47M
US$ 72.320M
NASDAQ SNSE SENSEI BIOTHERAPEUTICS
US$ 2.22
-0.05 -2.20
47,732
30.63M
US$ 68.000M
NASDAQ TERN TERNS PHARMACEUTICALS
US$ 2.69
0.21 8.47
111,555
25.28M
US$ 68.000M
NASDAQ MDNA MEDICENNA THERAPEUTICS
US$ 1.18
0.02 1.72
18,128
55.57M
US$ 65.570M
NYSEAMEX NHWK NIGHTHAWK BIOSCIENCES
US$ 2.55
0.00000 0.00000
21,114
25.65M
US$ 65.410M
NASDAQ RPHM RENEO PHARMACEUTICALS
US$ 2.65
0.00000 0.00000
84,058
24.46M
US$ 64.820M
OTCMKTS OTLC ONCOTELIC THERAPEUTICS
US$ 0.16
-0.00500 -2.94
91,700
369.70M
US$ 60.980M
NASDAQ MBIO MUSTANG BIO
US$ 0.59
0.00450 0.77
424,694
102.20M
US$ 60.250M
NASDAQ VTVT VTV THERAPEUTICS
US$ 0.72
-0.03 -3.96
48,290
77.33M
US$ 55.700M
OTCMKTS DTCFF DEFENCE THERAPEUTICS
US$ 1.52
0.00000 0.00000
0
36.05M
US$ 54.800M
OTCMKTS NGENF NERVGEN PHARMA
US$ 1.54
0.04 2.35
30,006
35.17M
US$ 53.990M
NASDAQ EFTR EFFECTOR THERAPEUTICS
US$ 1.31
-0.11 -7.75
43,776
41.10M
US$ 53.840M
NASDAQ CMRA COMERA LIFE SCIENCES
US$ 2.69
0.05 1.89
291,740
19.09M
US$ 51.350M
OTCMKTS ELTP ELITE PHARMACEUTICALS
US$ 0.05
-0.00200 -4.00
465,380
1.01B
US$ 48.480M
NASDAQ RDHL REDHILL BIOPHARMA
US$ 0.84
-0.03 -3.26
1.04M
53.26M
US$ 44.820M
NASDAQ GLTO GALECTO
US$ 1.70
-0.03 -1.73
15,069
25.26M
US$ 42.940M
NASDAQ INAB IN8BIO
US$ 2.22
-0.04 -1.77
1,093
18.84M
US$ 41.820M
NASDAQ GANX GAIN THERAPEUTICS
US$ 3.47
-0.13 -3.61
48,724
11.88M
US$ 41.220M
NASDAQ LBPH LONGBOARD PHARMACEUTICALS
US$ 2.95
-0.14 -4.53
4,820
13.59M
US$ 40.090M
NASDAQ NEXI NEXIMMUNE
US$ 1.72
0.11 6.83
32,460
22.84M
US$ 39.280M
NASDAQ CMMB CHEMOMAB THERAPEUTICS
US$ 3.32
-0.38 -10.27
36,461
11.40M
US$ 37.850M
NASDAQ CHEK CHECK-CAP
US$ 0.31
0.00400 1.29
162,002
116.41M
US$ 36.440M
NASDAQ IMMX IMMIX BIOPHARMA
US$ 2.60
0.00000 0.00000
273,141
13.88M
US$ 36.090M
NASDAQ ANGN ANGION BIOMEDICA
US$ 1.12
-0.02 -1.75
387,488
29.96M
US$ 33.560M
NASDAQ CRBP CORBUS PHARMACEUTICALS
US$ 0.26
0.00610 2.42
207,227
125.26M
US$ 32.350M
NASDAQ LGVN LONGEVERON
US$ 5.94
0.01 0.17
19,296
5.37M
US$ 31.900M
NASDAQ AGLE AEGLEA BIOTHERAPEUTICS
US$ 0.51
0.00500 0.99
247,766
61.17M
US$ 31.200M
OTCMKTS VPHIF VALEO PHARMA
US$ 0.39
0.00000 0.00000
0
78.85M
US$ 30.750M
NASDAQ HUGE FSD PHARMA
US$ 0.78
-0.01 -1.27
37,769
38.53M
US$ 30.050M
OTCMKTS MEDXF MEDEXUS PHARMACEUTICALS
US$ 1.54
0.00000 0.00000
230
19.17M
US$ 29.520M
OTCMKTS NBIO NASCENT BIOTECH
US$ 0.30
0.00800 2.76
70,054
97.06M
US$ 28.920M
OTCMKTS XPHYF XPHYTO THERAPEUTICS
US$ 0.45
0.05 11.20
200
64.24M
US$ 28.820M
NASDAQ LABP LANDOS BIOPHARMA
US$ 0.72
-0.01 -1.63
17,962
40.25M
US$ 28.820M
OTCMKTS EPWCF EMPOWER CLINICS
US$ 0.08
0.00270 3.60
5,675
333.40M
US$ 25.910M
NASDAQ AYTU AYTU BIOSCIENCE
US$ 0.67
-0.02 -2.90
3.40M
38.57M
US$ 25.840M
OTCMKTS ODYY ODYSSEY GROUP
US$ 0.25
0.00500 2.04
123,000
96.89M
US$ 24.220M
NASDAQ JAGX JAGUAR HEALTH
US$ 0.31
0.01 4.83
800,753
77.86M
US$ 24.000M
OTCMKTS HYEX HEALTHY EXTRACTS
US$ 0.07
0.00500 8.33
64,500
318.30M
US$ 20.690M
NASDAQ SBFM SUNSHINE BIOPHARMA
US$ 1.14
0.06 5.56
508,331
16.50M
US$ 18.810M
OTCMKTS ACOGF ALPHA COGNITION
US$ 0.30
-0.09 -22.68
2,000
61.02M
US$ 18.310M
NASDAQ RNXT RENOVORX
US$ 2.00
0.02 1.01
9,593
9.07M
US$ 18.140M
NASDAQ XRTX XORTX THERAPEUTICS
US$ 1.35
-0.06 -4.26
2,355
12.99M
US$ 17.540M
OTCMKTS BICX BIOCOR RX
US$ 2.45
-0.05 -2.00
457
6.96M
US$ 17.050M
OTCMKTS TBRIF THERMA BRIGHT
US$ 0.07
-0.03 -30.47
8,974
239.53M
US$ 16.890M
NASDAQ KTRA KINTARA THERAPEUTICS
US$ 0.26
-0.02 -8.27
964,981
65.53M
US$ 16.710M
NASDAQ LEXX LEXARIA BIOSCIENCE
US$ 2.76
-0.22 -7.38
58,565
5.95M
US$ 16.420M
NASDAQ BPTS BIOPHYTIS
US$ 1.09
-0.04 -3.54
6,756
14.75M
US$ 16.080M
NASDAQ UPC UNIVERSE PHARMACEUTICALS
US$ 0.66
0.03 4.73
9,098
21.75M
US$ 14.300M
OTCMKTS AQSZF AEQUUS PHARMACEUTICALS
US$ 0.09
0.00000 0.00000
0
132.63M
US$ 11.780M
OTCMKTS BIOAF BIOASIS TECHNOLOGIES
US$ 0.13
-0.00650 -4.86
100
72.91M
US$ 9.280M
NASDAQ PALI PALISADE BIO
US$ 0.40
-0.00920 -2.25
69,561
21.88M
US$ 8.730M
OTCMKTS SIGY SIGYN THERAPEUTICS
US$ 0.25
0.00000 0.00000
0
34.19M
US$ 8.540M
NASDAQ JAN JANONE
US$ 2.61
0.03 1.16
32,696
2.83M
US$ 7.390M
OTCMKTS APLIF APPILI THERAPEUTICS
US$ 0.06
0.00000 0.00000
0
121.27M
US$ 7.060M
OTCMKTS CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS
US$ 0.74
-0.01 -1.33
2.81M
9.51M
US$ 7.040M
OTCMKTS GDBYF GOODBODY HEALTH
US$ 0.02
0.00400 26.32
30,200
364.96M
US$ 7.000M
OTCMKTS BLMHF BLOOM HEALTH PARTNERS
US$ 0.16
0.00000 0.00000
0
39.04M
US$ 6.260M
NASDAQ KPRX KIORA PHARMACEUTICALS
US$ 0.45
-0.02 -4.38
260,517
12.66M
US$ 5.700M
OTCMKTS TRYPF TRYP THERAPEUTICS
US$ 0.09
-0.00800 -8.60
2,345
66.67M
US$ 5.670M
OTCMKTS SZLSF STAGEZERO LIFE SCIENCES
US$ 0.06
0.00000 0.00000
0
88.23M
US$ 5.640M
OTCMKTS NMLSF NOVA MENTIS LIFE SCIENCES
US$ 0.05
-0.00200 -3.92
25,850
111.14M
US$ 5.450M
OTCMKTS AGNPF ALGERNON PHARMACEUTICALS
US$ 3.00
0.09 3.09
1,153
1.67M
US$ 5.010M
OTCMKTS VYYRF VOYAGEUR PHARMACEUTICALS
US$ 0.09
0.00000 0.00000
0
51.46M
US$ 4.630M
OTCMKTS TRMNF NEW WAVE HOLDINGS
US$ 0.04
0.00000 0.00000
0
88.94M
US$ 3.380M
OTCMKTS PRXTF PURE EXTRACTS
US$ 0.03
0.00270 10.80
335,191
97.28M
US$ 2.690M
OTCMKTS KONEF WELLBEING DIGITAL SCIENCES
US$ 0.02
0.00000 0.00000
0
103.35M
US$ 2.170M
OTCMKTS FLURF FLUROTECH
US$ 0.00748
0.00000 0.00000
0
120.61M
US$ 902K
OTCMKTS LOBEF LOBE SCIENCES
US$ 0.01
0.00000 0.00000
0
-
US$ -
OTCMKTS MYNDF MYND LIFE SCIENCES
US$ 0.07
0.00000 0.00000
0
-
US$ -

BioTech Stock News

Green Stock News

Regeneron Pharmaceuticals Completes Purchase of Sanofi's Stake in Libtayo®

July 1, 2022

Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has completed the acquisition of Sanofi's stake in Libtayo® (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine... Read more

Green Stock News

Aequus Pharmaceuticals Provides General Update and Reports Record 2021 Financial Results

July 1, 2022

Also reports Financial Results for the 3 months ended March 31, 2022 Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a sales force that currently markets third party or exclusively licensed products for which the Company receives revenues from direct product sales and profit share arrangements, today reported financial... Read more

Green Stock News

Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study of Diabetes Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting, Acute Treatment for...

July 1, 2022

Biomea to present two oral abstracts across multiple animal models highlighting the ability of BMF-219, a covalent menin inhibitor, to significantly lower HbA1C (approximately two-fold greater reduction than active control, liraglutide) and to increase beta cell function. BMF-219 showed prolonged glycemic control in two standard diabetes animal models, the Zucker Diabetic Fatty (ZDF) and Stre... Read more

Green Stock News

Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors

July 1, 2022

Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced the appointment of Mathias Hukkelhoven, Ph.D., formerly Senior Vice President, Global Regulatory, Safety & Biometrics at Bristol... Read more

Green Stock News

BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder

June 30, 2022

BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that the first subject has been dosed in the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc.,... Read more

Green Stock News

Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update

June 30, 2022

All three FREEDOM-1 patients treated with FCR001 who are more than 12 months post-transplant have been successfully weaned off chronic anti-rejection drugs All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date have achieved and maintained >50% T-cell chimerism, a potential biomarker predictive of achieving tolerance Conference call scheduled for today... Read more

Green Stock News

Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine

June 29, 2022

105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new vaccine supply agreement with the U.S. government to support the continued fight against COVID-19. Under the agreement, the U.S. government will receive 105 million... Read more

Green Stock News

Lexicon Pharmaceuticals Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy

June 29, 2022

Study Supports Translation of Potential New Mechanism of Action for Neuropathic Pain and Advancement of LX9211 Development in Painful Diabetic Neuropathy Conference Call and Webcast at 8:00 a.m. Eastern Time June 30, 2022 Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced top-line results of RELIEF-DPN-1, its Phase 2 proof-of-concept study of LX9211 in painful diabetic neuropathy.... Read more

Green Stock News

Bionano Genomics Announces Issuance of a U.S. Patent for Analysis of Small Nucleic Acid Fragments in Nanochannel Arrays

June 29, 2022

Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that the United States Patent and Trademark Office issued US Patent No.11,359,244 on June 14, 2022. The patent, titled “CHARACTERIZATION OF MOLECULES IN NANOFLUIDICS” claims methods for the analysis of small nucleic acid fragments in nanochannel arrays, which Bionano has traditionally used to analyze ultra-high molecular weight... Read more

Green Stock News

Regeneron Pharmaceuticals: EYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review

June 29, 2022

If approved, extended regimen would provide a longer treatment interval and additional dosing flexibility, alongside approved every 4- and 8-week dosing regimens Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the EYLEA® (aflibercept) Injection supplemental Biologics License Application (sBLA)... Read more

Green Stock News

Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options

June 29, 2022

AbCellera (Nasdaq: ABCL) today announced that Eli Lilly and Company (Lilly) has entered into a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab, the second antibody developed through AbCellera’s collaboration with Lilly, for approximately $275 million. The existing U.S. government supply of bebtelovimab, including the new purchase, is expected... Read more

Green Stock News

Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Canalevia for Treatment of Diarrhea in Dogs in China

June 29, 2022

License fees of $5.0 million, and up to $5.0 million in unregistered equity infusion, over next 24 months Service agreement of up to $5.0 million payable in unregistered Jaguar stock to SynWorld to support approval of crofelemer in China, providing Jaguar Health with up to 80% of profits Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that the company has entered an exclusive license... Read more

Green Stock News

Elite Pharmaceuticals Receives FDA Approval for Generic Sabril

June 29, 2022

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a generic version of Sabril® (Vigabatrin USP) 500 mg powder for solution packet. Vigabatrin is an antiepileptic drug indicated... Read more

Green Stock News

Tryp Therapeutics Strengthens IP Portfolio with Provisional Patent Application for Binge Eating Disorder Treatment

June 29, 2022

Biotech Company Strengthens Strategic Intellectual Property Protection of Targeted Indication Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the filing of a new provisional patent for the use of psilocybin for the treatment... Read more

Green Stock News

Humacyte Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel™ to Expand Vascular Trauma Reconstruction and Bypass Treatment Options

June 29, 2022

HAV implanted in nearly 500 patients with more than 1,000 patient-years of follow up to date, for treatment of peripheral arterial disease, arteriovenous access for hemodialysis, and trauma Immediately-available HAV, if approved, would represent significant and innovative advancements for vascular repair and replacement conduits Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology... Read more

Green Stock News

Palisade Bio Initiates Phase 3 Study of LB1148 in Lead Indication for Postoperative Return of Bowel Function

June 29, 2022

Completion of enrollment for Phase 3 study targeted within 18-24 months In multiple clinical studies, LB1148 has demonstrated statistically significant acceleration in the time to the return of normal GI function, and has the potential to prevent damage to GI tissues and shorten the duration of costly post-surgery hospital stays Phase 3 study design utilizes same dosing protocol and same primary... Read more

Green Stock News

Odyssey Group Completes Safety Evaluation of Cohort II for Concussion Drug

June 29, 2022

Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-saving medical products, today announced positive safety findings from Cohort II of their Phase I clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. Data from Cohort II indicates that... Read more

Green Stock News

Appili Therapeutics Reports Fiscal Year 2022 Financial and Operational Results

June 29, 2022

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the fiscal year ended March 31, 2022, and provided an update on the Company’s strategy for fiscal 2023. All figures are stated in Canadian dollars unless otherwise... Read more

Green Stock News

VectivBio Announces Closing of $54 Million Aggregate Financing

June 29, 2022

VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announces it has closed each of its previously announced public offering of 6,467,688 ordinary shares, including the sale to the underwriters of 752,688 ordinary shares sold pursuant to the partial exercise of the underwriters’... Read more

Green Stock News

Adagene Announces Authorization of Share Repurchase Program up to US$10 Million

June 29, 2022

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that its board of directors has authorized a share repurchase program under which, Adagene may repurchase up to US$10 million of its ordinary shares in the form of American depositary shares, subject to the relevant rules under the Securities Exchange... Read more

Green Stock News

Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors

June 29, 2022

Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the appointment of Vivian Liu to the company's board of directors, effective July 1, 2022. Ms. Liu will serve as an independent director and as a member of the Nominating & Corporate Governance Committee. "I'm thrilled to welcome Vivian to Aytu's board of... Read more

Green Stock News

Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV

June 28, 2022

- IVX-121 demonstrated robust immunologic response to RSV, with comparable Geometric Mean Titer (GMT) levels achieved at Day 28 in both young and older adult groups - - IVX-121 was generally well tolerated with no vaccine-related SAEs - - Provides initial indication of a differentiated VLP platform technology - - Icosavax plans to file an IND submission and initiate a Phase 1 trial for IVX-A12,... Read more

Green Stock News

Certara Introduces New Simcyp™ Discovery Simulator for Early-Stage and Translational Drug Development

June 28, 2022

Certara (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Discovery Simulator, a new software designed for scientists working in small molecule drug discovery and translational research. Derived from the industry-leading Simcyp Simulator, Simcyp Discovery increases confidence in early-stage development decisions using physiologically-based pharmacokinetic (PBPK)... Read more

Green Stock News

Zomedica Announces Designation of PulseVet(R) System as the Official Shock Wave Therapy Supplier of the United States Equestrian Team

June 28, 2022

Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for equine and companion animals, is honored to announce that the United States Equestrian Federation (USEF) has named PulseVet as the Official Shock Wave Therapy Supplier of US Equestrian Team Veterinarians. "The USEF is pleased to partner with a company that... Read more

Green Stock News

Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update

June 28, 2022

Potential blockbuster VTAMA® (tapinarof) approved by FDA for the treatment of plaque psoriasis at end of May 2022 is the first topical novel chemical entity launched for plaque psoriasis in 25 years; product and samples are now available across the US, a robust patient support program is in place and a 100+ person commercial organization is fully deployed to target 4 million potential annual topical... Read more

Green Stock News

Roivant Sciences and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus

June 28, 2022

Roivant Sciences and Pfizer today announced the unveiling of Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity and mortality. Priovant was established in September 2021 through a transaction between Roivant (Nasdaq: ROIV) and Pfizer (NYSE: PFE), in which Pfizer licensed oral and topical brepocitinib’s global development... Read more

Green Stock News

Healthy Extracts Enters Retail Marketplace, Launching Brain Health Products in Over 160 Natural Grocers® Stores Nationwide

June 28, 2022

Healthy_Extracts' (OTCQB: HYEX) clinically proven, plant-based products for brain health are now shipping to more than 160 Natural Grocers® stores nationwide. Natural Grocers is the nation's largest family-operated organic and natural grocery retailer. The retailer also provides extensive free science-based nutrition education programs that help consumers make informed nutritional health... Read more

Green Stock News

JanOne Announces an Improved Formulation of JAN101

June 28, 2022

Recent Developments at the University of Iowa have Resulted in an Improved Formulation of JAN101 JanOne Inc. ("JanOne") (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that work has been completed by Dr. Maureen Donovan at the University of Iowa that will allow for an improved formulation of JAN101. JAN101 (formerly... Read more

Green Stock News

Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy

June 28, 2022

87% of patients who experienced ototoxicity in their placebo-treated ear were protected from ototoxicity in their DB-020-treated ear  Data support continued development of DB-020 as a potential therapy to protect against hearing loss in patients receiving cisplatin chemotherapy for cancer  Management will review results during a webcast today at 8:00 a.m. EDT  Decibel Therapeutics... Read more

ZOMEDICA

July 3, 2022

Read more

COPYRIGHT ©2022 GREEN STOCK NEWS